Neomorph, Inc.
Biotechnology ResearchCalifornia, United States51-200 Employees
Neomorph, Inc. is a clinical-stage biotechnology company based in San Diego, California, advancing a new class of therapies known as molecular glue degraders. By engineering neomorphic protein surfaces, it aims to induce selective degradation of disease drivers that have been historically undruggable, enabling precision targeting within cells. The company was founded in 2020. It has built what it describes as the world's largest proprietary molecular glue target space, spanning multiple novel degrons across an expansive portfolio of E3 ubiquitin ligases. The work is positioned to address serious diseases and to engage with researchers and pharmaceutical partners pursuing new therapeutic modalities. In May 2026, Neomorph announced the appointment of Bob Hugin as Chairman of its Board of Directors.
1-888-653-2347 
support@leadiq.com 
